VIA
MNPR icon

Virtus Investment Advisers’s Monopar Therapeutics MNPR Stock Holding History

Virtus Investment Advisers’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$507K Buy
5,474
+1,819
+50% +$113K 0.12% 209
2026
Q1 		$200K Buy
3,655
+90
+3% +$5.44K 0.06% 352
2025
Q4 		$233K Buy
+3,565
New +$291K 0.06% 353

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Virtus Investment Advisers's MNPR Position: Q2 2026 in Review

Virtus Investment Advisers increased its Monopar Therapeutics (MNPR) stake by 50% in Q2 2026, buying an estimated $113K and bringing the position to 5,474 shares worth $507K. The position accounts for 0.12% of the portfolio, ranked #209.

Virtus Investment Advisers first reported a position in MNPR in Q4 2025 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Virtus Investment Advisers held 5,474 shares of Monopar Therapeutics worth $507K as of Q2 2026.
  • Virtus Investment Advisers bought 1,819 Monopar Therapeutics shares in Q2 2026, an estimated $113K.
  • Monopar Therapeutics made up 0.12% of Virtus Investment Advisers's portfolio in Q2 2026, its #209 holding.
  • Virtus Investment Advisers first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.